Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A known ✓ | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.82 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.82 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GABRP | O00591 | 2/20 | 0.45 |
| ▸ | GABRD | O14764 | 2/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6907426 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL28199472 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL11284804 | 1.00 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL2223150 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL2223143 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL9261130 | 0.91 | TSHR (0.82) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL6875 | 0.91 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL615 | 0.91 | — | — | |
| Fumaric Acid SCHEMBL2046433 | 0.91 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL20487516 | 0.91 | TSHR (1.00) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-06-20 | — | — | US | disclosed |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20220105064-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | BIOGEN SWISS MFG GMBH (CH) | 2022-04-07 | — | — | US | disclosed |
| US-11229619-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2022-01-25 | — | — | US | disclosed |
| US-11224584-B2 | Sleep apnea treatment | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-18 | — | — | US | disclosed |
| US-11173123-B2 | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2021-11-16 | — | — | US | disclosed |
| US-20210220318-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | FWP IP APS (DK) | 2021-07-22 | — | — | US | disclosed |
| US-11052062-B2 | Controlled release pharmaceutical compositions comprising a fumaric acid ester | BIOGEN SWISS MANUFACTURING GMBH (CH) | 2021-07-06 | — | — | US | disclosed |
| US-20210179573-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | ARBOR PHARMACEUTICALS, LLC | 2021-06-17 | — | — | US | disclosed |
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | ARBOR PHARMACEUTICALS, LLC | 2021-05-20 | — | — | US | disclosed |
| US-20080004344-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | ADITECH PHARMA AB (SE) | 2008-01-03 | — | — | US | disclosed |
| EP-1812374-A1 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | Aditech Pharma AB (SE) | 2007-08-01 | — | — | EP | disclosed |
| EP-1799196-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | Aditech Pharma AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007042035-A2 | COMBINATION THERAPY WITH FUMARIC ACID ESTERS FOR THE TREATMENT OF AUTOIMMUNE AND/OR INFLAMMATORY DISORDERS | ADITECH PHARMA AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042034-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007006307-A2 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007006308-A1 | NOVEL GLUCOPYRANOSE ESTERS AND GLUCOFURANOSE ESTERS OF ALKYL- FU MARATES AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006050730-A1 | NOVEL SALTS OF FUMARIC ACID MONOALKYLESTERS AND THEIR PHARMACEUTICAL USE | ADITECH PHARMA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006037342-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER | ADITECH PHARMA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
| WO-2005027899-A1 | USE OF FUMARIC ACID DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF GENOME DAMAGE | HEIDLAND AUGUST (DE) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210145755-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | FH, MGMT, BHMT2 | MEN1 1773/4885KMT2A 434/4885TSHR 4205/4885 |
| US-20080004344-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | FAH, FH, SLC16A7 | MEN1 607/4885KMT2A 1800/4885TSHR 3293/4885 |
| US-20240024249-A1 | ORAL DOSAGE FORMS HAVING A HIGH LOADING OF A METHYL HYDROGEN FUMARATE PRODRUG | FH, MGMT, CYP4F2 | MEN1 1250/4885KMT2A 699/4885TSHR 4391/4885 |
| US-20240197661-A1 | ORAL DOSAGE FORMS OF METHYL HYDROGEN FUMARATE AND PRODRUGS THEREOF | MGMT, MTHFD2, PHF2 | MEN1 1158/4885KMT2A 629/4885TSHR 4207/4885 |
| US-20210179573-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | MEN1 1323/4885KMT2A 376/4885TSHR 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.